# Study on Androgen Receptor and Triple Negative Breast Cancer

> **NCT03383679** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 94 (actual)

## Conditions studied

- Breast Cancer Female
- Triple Negative and Androgen Receptor Positive

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03383679
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-14
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-07-20
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383679, "Study on Androgen Receptor and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03383679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*